Contact Us
Drug Search Results
More Filters [+]

Balixafortide

Alternative Names: balixafortide, pol-6326, pol6326, pol 6326, SPX5551, SPX-5551, SPX 5551
Latest Update: 2024-12-03
Latest Update Note: Clinical Trial Update

Product Description

Balixafortide (B) is a potent, selective antagonist of the chemokine receptor CXCR4. (Sourced from: https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.e15209)

Mechanisms of Action: CXCR4 Blocker

Novel Mechanism: Yes

Modality: Peptide/Protein

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Polyphor
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Balixafortide

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Breast Cancer

Phase 2: Multiple Myeloma|Acute Myeloid Leukemia|Acute Lymphoid Leukemia|Chronic Lymphoid Leukemia|Myeloproliferative Disorders|Chronic Myeloid Leukemia|Preleukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Leukemia, Plasma Cell|Lymphocytic Chronic B-Cell Leukemia|Myelodysplastic Syndrome|Lymphoma, B-Cell|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Lymphoma, Non-Hodgkin|ST Elevation Myocardial Infarction|Breast Cancer|Myocardial Infarction

Phase 1: Healthy Volunteers|Breast Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
NIR-II

N/A

Recruiting

Breast Cancer

2025-08-25

POLTER

P2

Withdrawn

Breast Cancer

2022-03-16

FORTRESS

P3

Terminated

Breast Cancer

2021-10-19

2018-004211-42

P3

Terminated

Breast Cancer

2021-03-28

Recent News Events

Date

Type

Title

10/13/2023

PubMed

 Development of a Rare Earth Nanoprobe Enables In Vivo Real-Time Detection of Sentinel Lymph Node Metastasis of Breast Cancer Using NIR-IIb Imaging.

09/01/2023

PubMed

 A CXCR4 inhibitor (balixafortide) enhances docetaxel-mediated antitumor activity in a murine model of prostate cancer bone metastasis.

12/13/2022

News Article

 Spexis announces promising pre-clinical data with balixafortide in combination with various therapies on the market for treating B-cell lymphomas

09/22/2022

News Article

 Spexis announces positive renal impairment clinical trial results with balixafortide

07/28/2022

News Article

 Spexis provides business update

07/07/2022

News Article

 Spexis' CXCR4 inhibitor balixafortide demonstrates synergistic efficacy in combination with docetaxel in a metastatic prostate cancer preclinical model

06/30/2021

PubMed

 Macrocycle Therapeutics to Treat Life-threatening Diseases.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions